Literature DB >> 29192333

Individual benefits of enoxaparin treatment in branch vein occlusion.

Francesco Dragoni1, Kai Kaarniranta2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29192333     DOI： 10.1007/s00417-017-3854-z

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  5 in total

1.  Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison.

Authors:  Ahmed S Gado; Tamer A Macky
Journal:  Clin Exp Ophthalmol       Date:  2014-04-01       Impact factor: 4.207

Review 2.  Retinal vein occlusions: a review for the internist.

Authors:  Rossella Marcucci; Francesco Sofi; Elisa Grifoni; Andrea Sodi; Domenico Prisco
Journal:  Intern Emerg Med       Date:  2010-12-14       Impact factor: 3.397

3.  Retinal and orbital venous occlusions treated with enoxaparin.

Authors:  Robert D Steigerwalt; M Rosaria Cesarone; Gianni Belcaro; Pierpaolo Quercioli; Giorgio Lofoco; Francesco Ciucci; Antonella Pascarella; Mauro De Angelis; Laura Rapagnetta; Marcella Nebbioso
Journal:  J Ocul Pharmacol Ther       Date:  2008-08       Impact factor: 2.671

4.  Baseline and early natural history report. The Central Vein Occlusion Study.

Authors: 
Journal:  Arch Ophthalmol       Date:  1993-08

Review 5.  Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.

Authors:  José Tuñón; José María Ruiz-Moreno; José Luis Martín-Ventura; Luis M Blanco-Colio; Oscar Lorenzo; Jesús Egido
Journal:  Surv Ophthalmol       Date:  2009 May-Jun       Impact factor: 6.048
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.